Core Insights - NANO Nuclear Energy Inc. has successfully completed initial full-system testing of its proprietary Annular Linear Induction Pump (ALIP), validating key design features aimed at long-term operational durability [1][5] - The ALIP is designed for advanced small and micro modular reactor applications, utilizing high boiling-point, high thermal-conductivity coolants [2][7] - The testing was conducted in collaboration with aRoboticsCompany, focusing on enhancing the pump's lifespan in maintenance-free environments such as space and undersea applications [4][5] Technology Development - The ALIP functions as a thermal management and distribution system, employing electromagnetic pumping mechanisms to improve reliability and reduce maintenance needs [2][9] - Recent tests confirmed the effectiveness of design modifications aimed at increasing magnetic field strength and overall system performance [5][9] - A full stack of precision manufacturing processes and electromagnetic quality control systems were validated, ensuring consistent production of ALIPs [6] Commercialization Progress - NANO Nuclear is moving towards the next phase of its ALIP commercialization program, positioning the technology as a zero-maintenance alternative to mechanical pumps [7][9] - The company aims to enhance the reliability, lifespan, and efficiency of the ALIP while reducing production costs [6] - The successful testing outcomes are expected to guide future design decisions and strengthen the company's long-term development roadmap [9] Company Overview - NANO Nuclear Energy Inc. is focused on becoming a diversified and vertically integrated company across multiple business lines, including microreactor technologies and nuclear fuel fabrication [10][11] - The company is developing several advanced reactor products, including the KRONOS MMR™ Energy System and the portable LOKI MMR™, aimed at clean energy solutions [11] - NANO Nuclear's subsidiaries are working on various aspects of the nuclear energy supply chain, including fuel transportation and space applications [12][14]

Constellation Energy will receive a $1 billion loan to restart Three Mile Island, which has been renamed the Crane Clean Energy Center. ...

Meanwhile, uh, the Trump administration is going to provide Constellation Energy with a $1 billion loan to restart the Crane Clean Energy Center nuclear plant. That's in Pennsylvania. The site was formerly known as 3M Island uh, Unit One.Stopped operating in 2019, but last year, Constellation unveiled plans to rename and restart the reactor through a power purchase deal with Microsoft to support data center demand. It's expected to begin generating power in 2027. That reactor sits on the same site as Three- ...

RESTON, Va., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), a leader in advanced nuclear fuel technology, today announced the start of irradiation testing of its enriched uranium-zirconium alloy fuel material samples in the Advanced Test Reactor (ATR) at Idaho National Laboratory (INL). This milestone represents a significant step forward in the Company’s fuel development and testing program conducted under its Cooperative Research and Development Agreement (CRADA) with INL. Imag ...

Industry Development - US-Saudi Arabia negotiations on nuclear-technology-sharing deal completed [1] - This potentially opens opportunities for American companies to construct reactors in Saudi Arabia [1]

The Trump administration will give Constellation Energy a $1 billion federal loan to restart the Three Mile Island nuclear power plant in Pennsylvania that suffered a partial core meltdown in 1979. https://t.co/93eO0vEwTq ...

Using secret recordings of conversations in flats and back offices around Kyiv, Ukraine’s anti-corruption bodies documented a scheme to embezzle at least $100m from the state nuclear company. The details are excruciating https://t.co/4XpYfdHJJ9 ...

Core Insights - 2025 has seen significant investment themes including artificial intelligence, quantum computing, and notably, nuclear energy stocks, with the VanEck Uranium and Nuclear ETF delivering a total return of 55% as of November 17 [2] Company Performance - NuScale Power experienced a tumultuous year, with shares rising nearly 200% through mid-October but subsequently collapsing by around 61% from their peak due to disappointing Q3 earnings [3][6] - The company reported a substantial loss of $1.85 per share against analyst expectations of a loss of only 11 cents, primarily due to a $128.5 million payment to ENTRA1 Energy aimed at expediting a six-gigawatt nuclear energy deployment [4][5] - Following the earnings report, NuScale's shares dropped 14% on November 6 and continued to decline, resulting in a total decrease of 45% since the report, with Royal Bank of Canada lowering its price target from $35 to $32 [5] Market Reactions - Constellation Energy, the largest operator of nuclear energy facilities in the U.S., reported Q3 earnings on November 7, missing both sales and adjusted EPS expectations, yet the stock gained 2% on the same day [7] - Despite a 16% decline from mid-October highs, Constellation has still achieved a total return of 52% year-to-date [7]

ATS Corporation Conference Call Summary Company Overview - **Company**: ATS Corporation (NYSE: ATS) - **Date**: November 18, 2025 - **Speaker**: Ryan McLeod, Interim CEO Key Points Industry and Market Dynamics - **Life Sciences Sector**: ATS has six independent life science businesses, with a focus on automation and drug delivery mechanisms, particularly auto injectors, which account for approximately 10% of total revenues and 20% of life science revenues [7][15][16] - **Growth in GLP-1 Market**: The GLP-1 segment is expected to remain a significant revenue contributor over the next five years, with high growth potential due to increasing consumer demand for drug delivery devices [15][23] - **Radiopharma Growth**: Investment in radiopharmaceuticals for cancer treatment is driving growth, with a shift towards personalized medicine leading to more specific therapies [17][18] - **Wearable Devices**: ATS is involved in the development of wearable devices, expanding their market from diabetes treatment to general consumer applications [19][20] Financial Performance - **Q2 Fiscal Results**: Revenues increased by approximately 12% year-over-year, with a backlog growth of 13.5% [11][12] - **Margin Expansion**: ATS is on track for high single-digit organic growth and has seen sequential margin expansion, particularly in Q2 [12][13] - **Transportation Segment**: The transportation business has stabilized at around $50 million per quarter, with no expected growth in the next three to five years due to market saturation and technology changes [30][31] Strategic Initiatives - **Restructuring and Optimization**: ATS has undergone significant restructuring to optimize performance, particularly in the transportation segment, while exploring adjacent opportunities in industrial manufacturing and reshoring [31][33] - **Nuclear Business Growth**: The nuclear segment is expected to grow, with a focus on refurbishment, decommissioning, and new builds, particularly in the context of increasing energy demands [25][27][28] Leadership Transition - **CEO Search**: The board is actively engaged in the search for a new CEO, prioritizing candidates with strong backgrounds in continuous improvement and M&A [56][59] Other Considerations - **Working Capital Management**: ATS aims to reduce working capital investment from approximately 18% to a target of 15% of sales, with larger life science programs expected to contribute to this goal [46][48] - **Market Positioning**: ATS is focused on high-consequence markets such as life sciences and food, which are less cyclical and emphasize quality and time to market [44][45] This summary encapsulates the key insights from the ATS Corporation conference call, highlighting the company's strategic focus, market dynamics, and financial performance.

Key Takeaways OKLO posted another quarterly miss as the stock fell sharply from recent highs.Broader losses and uncertain regulatory timelines underscore rising execution risks.Lack of binding commercial deals and dilution concerns add pressure to OKLO's outlook.Last week, Oklo Inc. (OKLO) delivered another disappointing quarter, marking its third miss in the last four reporting periods, and forcing investors to re-evaluate whether the hype-driven rally still makes sense. The stock has also pulled back shar ...